Treating Patients with Complex Metabolic Conditions

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Year Invested: 2011
Location: Newton, Mass.

Recent News

December 14, 2017
Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

November 1, 2017
Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

July 27, 2017
European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals' Investigational Therapy for the Treatment of Primary Hyperoxaluria

Read More News

Associated Team Members

Robert Tepper, M.D.